Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · head-neck@1

SRR25043629

—

f4810fdd-fafe-563d-8db2-ddf11bfb1ef9

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • INTERFERON_ALPHA_RESPONSE+0.580
  • INTERFERON_GAMMA_RESPONSE+0.460
  • PROTEIN_SECRETION+0.410
  • TNFA_SIGNALING_VIA_NFKB+0.380
  • IL6_JAK_STAT3_SIGNALING+0.330
  • INFLAMMATORY_RESPONSE+0.320
  • HYPOXIA+0.310
  • TGF_BETA_SIGNALING+0.300
  • COMPLEMENT+0.270
  • UV_RESPONSE_DN+0.250

Top 10 suppressed

  • PANCREAS_BETA_CELLS-0.340
  • DNA_REPAIR-0.270
  • OXIDATIVE_PHOSPHORYLATION-0.200
  • WNT_BETA_CATENIN_SIGNALING-0.200
  • REACTIVE_OXYGEN_SPECIES_PATHWAY-0.170
  • E2F_TARGETS-0.140
  • NOTCH_SIGNALING-0.100
  • ANGIOGENESIS-0.070
  • EPITHELIAL_MESENCHYMAL_TRANSITION-0.070
  • ADIPOGENESIS-0.060

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1TCGA-CV-6952-01A-11R-1915-07
head-neck@1
——0.858
2TCGA-K4-A6FZ-01A-11R-A31N-07
bladder-landscape@3
——0.856
3SRR23036887
head-neck@1
——0.849
4TCGA-CV-7427-01A-11R-2081-07
head-neck@1
——0.812
5MNG1215
mng-umap@100
——0.808
6TCGA-CQ-7063-01A-11R-2403-07
head-neck@1
——0.795
7SJEPD030232_D1.RNA-Seq
medullo-epn-umap@date-based
EPNPosterior Fossa EPN0.794
8TCGA-CN-6998-01A-23R-2016-07
head-neck@1
——0.793
9MNG464
mng-umap@100
——0.791
10SJEPD032296_D1.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.790

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 35 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
INTERFERON_ALPHA_RESPONSE0.580Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.460Idelalisib— uncovered
PROTEIN_SECRETION0.410Remibrutinib— uncovered
TNFA_SIGNALING_VIA_NFKB0.380Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.330Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.320Idelalisib— uncovered
HYPOXIA0.310Idelalisib— uncovered
TGF_BETA_SIGNALING0.300Inavolisib— uncovered
COMPLEMENT0.270Inavolisib— uncovered
UV_RESPONSE_DN0.250Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.240Remibrutinib— uncovered
MTORC1_SIGNALING0.210Inavolisib— uncovered
ANDROGEN_RESPONSE0.200Inavolisib— uncovered
MITOTIC_SPINDLE0.200Inavolisib— uncovered
KRAS_SIGNALING_UP0.190Inavolisib— uncovered
PI3K_AKT_MTOR_SIGNALING0.190Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.190Idelalisib— uncovered
ALLOGRAFT_REJECTION0.180Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.180Idelalisib— uncovered
HEME_METABOLISM0.150Temsirolimus— uncovered